

EAHAD 2019 - Abstract Submission

Regular abstract

EAHAD19-ABS-1439

FOSTERING DRUG STORAGE, PREPARATION AND TREATMENT MODALITIES IMPROVES ADHERENCE TO TREATMENT WITH TUROCTOCOG-ALFA IN PATIENTS WITH HAEMOPHILIA A: RESULTS FROM A SHORT-TERM FOLLOW-UP

Mariasanta Napolitano¹, Renato Marino², Erminia Bldacci³, Antonella Coluccia⁴, Dorina Cultrera⁵, Matteo Luciani⁶, Samantha Pasca⁷, Lisa Pieri⁸, Irene Ricca⁹, Giovanni Barillari¹⁰, Cosimo Ettore¹¹, Silvia Linari¹², Federica Valeri¹³, Sergio Siragusa¹⁴, Angiola Rocino¹⁵

¹Internal Medicine and Specialties Department (DiBIMIS), Università di Palermo, Palermo, ²Haemophilia Center, Policlinico di Bari, Bari, ³Haematology Department, "Gemelli" University Hospital, Roma, ⁴Internal medicine, General Hospital, Lecce, ⁵Hematology Department, University Hospital, Catania, ⁶Hematology Department, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, ⁷Haemophilia Center, University Hospital of Padova, Padova, ⁸Haematology Department, University Hospital "Careggi", Firenze, ⁹Transfusion Center, CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO, Torino, ¹⁰Haemophilia and Thrombosis Center, barillarigiovanni@yahoo.it, Udine, ¹¹Haemophilia and thrombosis Center, University Hospital of Bari, Bari, ¹²Haematology Unit, University Hospital "Careggi", Firenze, ¹³Haematology Unit, Azienda Ospedaliera San Giovanni Battista, Torino, ¹⁴DiBIMIS, Università di Palermo, Palermo, ¹⁵Haematology Unit and Reference Regional Center, Hospital "Loreto Mare", Napoli, Italy

Introduction: Adherence to treatment in haemophilia A is crucial to allow good clinical outcomes. Several drug-related aspects including storage flexibility (temperature), reconstitution device, and administration frequency, have been recently reported to affect patient satisfaction (Patient Prefer Adherence. 2018 Mar 26;12:431-441). Aim of the current prospective analysis was to evaluate any change in treatment adherence measures after switching to turoctocog-alfa (Novoeight®) for treatment of patients with haemophilia A

Methods: Patients enrolled in the current prospective analysis were asked to fill the Veritas-Pro questionnaire (Haemophilia. 2010 Mar;16(2):247-55) before switching and up to three months after starting treatment with turoctocog-alfa. Indication to start treatment with turoctocog-alfa were based on clinical needs and patients' style of life. At each clinical encounter, aspects related to drug storage, preparation and reconstitution were accurately described.

Results: Update, 11 patients have been followed-up for three months. Turoctocog-alfa resulted effective and safe in all cases. The median global score at first administration was 36 (SD:17), while it decreased to 33 (SD:14.28) at 3 months follow-up. The majority of subjects (N=8) received prophylaxis for severe haemophilia A and started to store their drug outside the refrigerator only after the first clinical encounter.

Discussion/Conclusion: Current results confirm that better communication from health care providers to explain product storage and administration modalities of a room temperature (up to 40°C) stable drug is able to further improve adherence to treatment, at least in the short term.

Disclosure of Interest: None Declared